Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677499 | 0.85 | HSD17B1 (0.36) | — | |
| SCHEMBL3688180 | 0.82 | ESR1 (0.32) | — | |
| SCHEMBL3683441 | 0.82 | TTR (0.38) | CYP2C9 | |
| SCHEMBL3681486 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL3683675 | 0.78 | ESR2 (0.36) | — | |
| SCHEMBL3684902 | 0.78 | ESR2 (0.36) | — | |
| SCHEMBL3676121 | 0.78 | ESR2 (0.36) | — | |
| SCHEMBL3673278 | 0.77 | KDM4E (0.34) | CYP2C9 | |
| SCHEMBL3680283 | 0.76 | MELK (0.33) | CYP2C9 | |
| SCHEMBL3688360 | 0.76 | EP300 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | claimed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | claimed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | CA1 2323/4885CA2 2060/4885CYP2C9 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.